Is Avid Bioservices, Inc. (CDMO) a Buy, Sell, or Hold?
NASDAQ : CDMO
Avid Bioservices, Inc.
$12.49 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 1.58M
- Market Capitalization
- $798.9M
- P/E Ratio
- -5.60
- Dividend Yield
- 0.00%
- Price Target
- $8.00
- Year High
- $12.51
- Year Low
- $5.90
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.47
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Nicholas Stewart Green MBA |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CDMO |
| CUSIP | 05368M106 |
| CIK | 0000704562 |
| Web | https://www.avidbio.com |
| Phone | 714 508 6100 |
| Currency | USD |
| Employees | 371 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 3.41 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.47 |
| Quick Ratio | 1.04 |
| Cash Ratio | 0.54 |
Sales & Book Value
| Annual Sales | $139.91M |
| Price / Sales | 5.71 |
| Cash Flow | -0.33 |
| Price / Cash Flow | -38.31 |
| Price / Book | 12.96 |
Price Target and Rating
| Average Stock Price Forecast | $8.00 |
| High Stock Price Forecast | $8.00 |
| Low Stock Price Forecast | $8.00 |
| Forecast Upside/Downside | 56.13% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$2.23 |
| Trailing P/E Ratio | -5.60 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | -$140.75M |
| Net Margin | -100.60% |
| Pretax Margin | -19.25% |
| Return on Equity | -112.44% |
| Return on Assets | -41.82% |
Financials Score
| AltmanZ Score | -0.58 |
| Piotroski Score | 3.00 |
| Working Capital | 22.35M |
| Total Assets | 323.48M |
| Ebit | -26.81M |
| Market Cap | 798.9M |
| Total Liabilities | 278.67M |
Poll Results
About Avid Bioservices, Inc. (NASDAQ:CDMO) Stock
Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO), specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. Their core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions. The company is proficient in producing critical therapeutics such as monoclonal antibodies and recombinant proteins. Beyond manufacturing, their comprehensive service portfolio encompasses CGMP manufacturing for drug substances, bulk packaging, rigorous release and stability testing, and essential regulatory submission and support. Additionally, Avid Bioservices offers a range of process development services, including the optimization of upstream and d ... ownstream processes, alongside the development, testing, and characterization of analytical methods. Avid Bioservices primarily serves clients within the biotechnology and biopharmaceutical industries. The company, which was originally incorporated in 1981, was known as Peregrine Pharmaceuticals, Inc. before officially rebranding to Avid Bioservices, Inc. in January 2018. Its corporate headquarters are situated in Tustin, California.
Kimball Electronics Acquires European-Based Medical CDMO, Helvoet Polymer Technologies B.V.
2026-07-01 02:00:00
JASPER, Ind.--(BUSINESS WIRE)--Kimball Electronics, Inc. (Nasdaq: KE) today announced the Company acquired Helvoet Polymer Technologies B.V. (“Helvoet”), a Contract Development and Manufacturing Organization (CDMO), based in Europe and with operations in India focused on microfluidics, diagnostics, and drug delivery. The transaction was valued at a purchase price of €90 million (excluding working capital, other customary adjustments, and acquisition-related costs), or approximately $103 million.
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
2026-06-22 05:00:00
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits PR Newswire MUMBAI,
2026-06-18 09:05:00
BLUE ASH, Ohio, June 18, 2026 (GLOBE NEWSWIRE) -- Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today announced the relocation of Resilience's corporate headquarters from San Diego, California to Blue Ash, Ohio, a northern suburb of Cincinnati. Resilience is a leading biomanufacturing contract and development manufacturing organization (CDMO) dedicated to broadening access to complex medicines, with a large drug product manufacturing facility in West Chester, Ohio. This move strengthens the company's operational footprint in the state, and reinforces Ohio's position as a growing hub for pharmaceutical and sterile manufacturing innovation.
2026-06-16 08:45:00
MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc's Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company's lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors.
2026-06-11 08:00:00
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
2026-06-10 07:55:00
JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update.
2026-06-04 00:00:00
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEMÂ in the U.S.
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
2026-05-20 07:00:00
JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd.
Frequently Asked Questions
-
What is the current Avid Bioservices, Inc. (CDMO) stock price?
-
Avid Bioservices, Inc.(NASDAQ:CDMO) stock price is $12.49 in the last trading session. During the trading session, CDMO stock reached the peak price of $12.51 while $5.9 was the lowest point it dropped to. The percentage change in CDMO stock occurred in the recent session was 0.0% while the dollar amount for the price change in CDMO stock was $0.
-
CDMO's industry and sector of operation?
-
The NASDAQ listed CDMO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CDMO?
-
Daniel R. Hart | Chief Financial Officer
Matthew Kwietniak | Chief Commercial Officer
Nicholas Stewart Green | President, Chief Executive Officer & Director
Richard Richieri | Chief Operations Officer
Mark R. Ziebell | Vice President, General Counsel & Corporate Secretary -
How many employees does CDMO have?
-
Number of CDMO employees currently stands at 371. CDMO operates from 2642 Michelle Drive, Tustin, CA 92780, US.
-
Link for CDMO official website?
-
Official Website of CDMO is: https://www.avidbio.com
-
How do I contact CDMO?
-
CDMO could be contacted at phone #714 508 6100 and can also be accessed through its website. CDMO operates from 2642 Michelle Drive, Tustin, CA 92780, US.
-
How many shares of CDMO are traded daily?
-
The average number of CDMO shares traded daily for last 3 months was 1.58M.
-
What is the market cap of CDMO currently?
-
The market value of CDMO currently stands at $798.9M with its latest stock price at $12.49